Additionally, IL-17/IL-23 axis blockade using agents such as secukinumab or guselkumab has shown efficacy in suppressing γδ T cell–mediated inflammation, though clinical outcomes in RA remain modest due to cytokine redundancy. This evidence concerns the gene IL17A and rheumatoid arthritis.